From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.
News|Articles|August 1, 2025
6 Allergy Headlines You Missed in July 2025
Author(s)Chelsie Derman
Fact checked by: Victoria Johnson
This month in review spotlights 6 headlines, from the FDA approving sebetralsta for HAE to NICE Recommending Betula Verrucosa for Birch Tree Allergy.
Advertisement
Advertisement
Several key studies and recommendations signaled meaningful shifts in clinical practice for the
Related to this article
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
Advertisement
Advertisement